Abstracts tagged "osteoporosis"

Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 380 • 2015 ACR/ARHP Annual Meeting
Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Sheena Ogando¹, Calie Santana², Irene Blanco³ and Barbara Mendez¹, ¹Rheumatology, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucocorticoids are effective at treating rheumatologic diseases but are known to increase fracture risk. In 2010, the ACR developed recommendations for the prevention…
Abstract Number: 2314 • 2014 ACR/ARHP Annual Meeting
Dexa Testing in Long-Term Steroid Use
Beth Scholz, Internal medicine, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Risk stratification in the ACR glucocorticoid-induced osteoporosis guidelines includes DEXA testing, which is not universally implemented at our rheumatology clinic. DEXA utilization should be…
Abstract Number: 2315 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting
Hajra Shah, Narender Annapureddy, Joel A. Block and Ruchi Jain, Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: One-fourth of hip fractures occur in men. Three groups of men are at high risk for fracture: those who have already suffered a fragility…
Abstract Number: 2259 • 2014 ACR/ARHP Annual Meeting
Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis
Makoto Kaburaki, Kaichi Kaneko, Kotaro Shikano, Mai Kawazoe, Emiko Shindo, Hiroshi Sato, Natsuki Fujio, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Natsuko Kusunoki, Tomoko Hasunuma, Shinichi Kawai and Shotaro Masuoka, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose ,Osteoporosis is one of the serious complications of systemic glucocorticoid therapy. Reduced bone formation is the key process in patients with glucocorticoid-induced osteoporosis (GIOP),…
Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Robert A. Overman¹ and Chad L. Deal², ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…
Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
McCall Walker¹, Harmanjot K. Grewal², Adam Janot³, Mary Yu⁴, Sophia Cenac⁵, Matthew R. Lammi^6,7 and Lesley Ann Saketkoo⁸, ¹LSUHSC School of Medicine, New Orleans, LA, ²Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ³Department of Ophthalmology, Virginia Commonwealth University –Medical College of Virginia, Charlottesville, VA, ⁴Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁷Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁸Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…
Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Akhila Balasubramanian¹, Sally Wade², Robert A Adler³, Celia Fang (Lin)⁴, Michael Maricic⁵, Cynthia O'Malley¹, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁴Amgen, Thousand Oaks, CA, ⁵Catalina Pointe Rheumatology, Tucson, AZ, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…
Abstract Number: 916 • 2014 ACR/ARHP Annual Meeting
Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density
MR McClung¹, A Chines², JP Brown³, A Diez-Perez⁴, H Resch⁵, J Caminis⁶, MA Bolognese⁷, S Goemaere⁸, HG Bone⁹, JR Zanchetta¹⁰, J Maddox², O Rosen², S Bray¹¹ and A Grauer², ¹Oregon Osteoporosis Center, Portland, OR, ²Amgen Inc., Thousand Oaks, CA, ³Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, ⁴Autonomous University of Spain, Barcelona, Spain, ⁵St. Vincent Hospital, Vienna, Austria, ⁶UCB, Raleigh, NC, ⁷Bethesda Health Research Center, Bethesda, MD, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Michigan Bone and Mineral Clinic, Detroit, MI, ¹⁰Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹¹Amgen Ltd., Cambridge, United Kingdom
Background/Purpose: We previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone…
Abstract Number: 232 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis
Kotaro Shikano, Kaichi Kaneko, Mai Kawazoe, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is known as a cause of secondary osteoporosis. The previous studies reported that receptor activator for nuclear factor κB ligand (RANKL)…
Abstract Number: 111 • 2014 ACR/ARHP Annual Meeting
Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy
Mamatha Siricilla¹, Ruili Luo², Linda Elting² and Maria E. Suarez-Almazor¹, ¹The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Aromatase inhibitors (AI) are increasingly used as adjuvant hormonal therapy in postmenopausal women with estrogen receptor-positive breast cancer. It is well recognized that therapy…
Abstract Number: 50 • 2014 ACR/ARHP Annual Meeting
Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study
Diogo S. Domiciano¹, Luana G. Machado², Jaqueline B. Lopes², Valéria Caparbo², Liliam Takayama², Ricardo M. Oliveira³ and Rosa M. R. Pereira⁴, ¹Rheumatology, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³RDO Diagnosticos Medicos, São Paulo, Brazil, ⁴Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: Vertebral fractures are associated with increased future fracture risk and mortality. No data on incidence of osteoporotic vertebral fracture have been reported in low-income…
Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Gene Marcantonio¹, Chengcheng Liu², Stefan Zajic³, Chantal Mahon², David Hreniuk², Anish Mehta⁴, Kate Mostoller², Denise Morris⁵, Hongwei Xue⁵ and S. Aubrey Stoch², ¹Merck & Co., Whitehouse Station, NJ, ²Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ³Merck Sharp & Dohme Corp, Whitehouse Station, NJ, ⁴Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, ⁵Covance, Madison, WI
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…
Abstract Number: 1226 • 2013 ACR/ARHP Annual Meeting
Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score
Jennifer Watt¹, Andrew E. Thompson², Nicole G. H. Le Riche³ and Janet E. Pope⁴, ¹Medicine, University of Western Ontario, London, ON, Canada, ²Rheumatology, St. Josephs Health Ctr, London, ON, Canada, ³Department of Medicine, St. Joseph's Hospital, London, ON, Canada, ⁴Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].